Compare UK & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UK | SXTP |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | China | United States |
| Employees | 42 | 3 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | UK | SXTP |
|---|---|---|
| Price | $2.98 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | ★ 341.0K | 132.7K |
| Earning Date | 03-24-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.34 |
| 52 Week High | $5.90 | $8.62 |
| Indicator | UK | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 71.40 | 40.78 |
| Support Level | $0.75 | $1.55 |
| Resistance Level | N/A | $1.84 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | 0.27 | 0.01 |
| Stochastic Oscillator | 50.36 | 6.65 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, and Other services. The Workspace membership segment generates the majority of the company's revenue.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.